OctoPlus' licensee Biolex commences Phase IIb study with Locteron
In October 2008 OctoPlus entered into an exclusive license and product acquisition agreement with Biolex, worth up to € 100 million. As a result, Biolex holds the full commercial rights to Locteron and is responsible for development and commercialisation, and OctoPlus is paid by Biolex to perform process development and to manufacture Locteron.
The Phase IIb study is being conducted in the United States and Europe in 100 treatment-naïve, genotype-1, chronic hepatitis C patients. Patients will be randomised into one of four dosing cohorts, the 320, 480 or 640 µg dose of Locteron (administered once every two weeks) or a control arm consisting of PEG-Intron® (administered every week), with all patients receiving weight-based ribavirin. Patients will be treated for 48 weeks and will be followed for an additional 24 weeks to determine the sustained virologic response (SVR) rate. The interim results after 12 weeks of treatment are expected to be used as the basis for the selection of the Locteron dose(s) for Phase III studies.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.